Our top pick for
Plus Therapeutics, Inc is a biotechnology business based in the US. Plus Therapeutics shares (PSTV) are listed on the NASDAQ and all prices are listed in US Dollars. Plus Therapeutics employs 12 staff and has a trailing 12-month revenue of around USD$1.5 million.
|Latest market close||USD$2.04|
|52-week range||USD$0.931 - USD$3.56|
|50-day moving average||USD$2.222|
|200-day moving average||USD$2.3814|
|Wall St. target price||USD$5.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-27.9754|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-6.42%|
|1 month (2020-12-16)||-0.49%|
|3 months (2020-10-15)||-20.31%|
|6 months (2020-07-15)||-3.77%|
|1 year (2020-01-15)||-25.01%|
|2 years (2019-01-15)||568.85%|
|3 years (2018-01-12)||476.27%|
|5 years (2016-01-15)||1,269.13%|
Valuing Plus Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Plus Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Plus Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Plus Therapeutics shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$1.5 million|
|Gross profit TTM||USD$1.6 million|
|Return on assets TTM||-25.49%|
|Return on equity TTM||-268.54%|
|Market capitalisation||USD$9.8 million|
TTM: trailing 12 months
There are currently 111,257 Plus Therapeutics shares held short by investors – that's known as Plus Therapeutics's "short interest". This figure is 29.3% down from 157,283 last month.
There are a few different ways that this level of interest in shorting Plus Therapeutics shares can be evaluated.
Plus Therapeutics's "short interest ratio" (SIR) is the quantity of Plus Therapeutics shares currently shorted divided by the average quantity of Plus Therapeutics shares traded daily (recently around 94285.593220339). Plus Therapeutics's SIR currently stands at 1.18. In other words for every 100,000 Plus Therapeutics shares traded daily on the market, roughly 1180 shares are currently held short.
However Plus Therapeutics's short interest can also be evaluated against the total number of Plus Therapeutics shares, or, against the total number of tradable Plus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Plus Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Plus Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0233% of the tradable shares (for every 100,000 tradable Plus Therapeutics shares, roughly 23 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Plus Therapeutics.
Find out more about how you can short Plus Therapeutics stock.
We're not expecting Plus Therapeutics to pay a dividend over the next 12 months.
Plus Therapeutics's shares were split on a 1:50 basis on 6 August 2019. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Plus Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Plus Therapeutics shares which in turn could have impacted Plus Therapeutics's share price.
Over the last 12 months, Plus Therapeutics's shares have ranged in value from as little as $0.931 up to $3.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Plus Therapeutics's is 0.4378. This would suggest that Plus Therapeutics's shares are less volatile than average (for this exchange).
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.